Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Study of MK-1708 in Healthy Japanese Participants
jRCT2071240035Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-1708 in Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) (7 arms), sponsored by Merck & Co. Primary endpoints: Safety (Adverse Events) and Discontinuations due to Adverse Events. Started Aug 2024; status: completed.
02
Drugs
mk-1708
03
Conditions
Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2071240035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240035.